Introduction
Let me give a few introductory remarks and see if I can stir up some questions. cess. Both of them will be a carryover of the last two discussions we've had.
The first issue is the so-called first step of transformation, which is the formation of an initiated cell. The formation of an initiated cell is in itself at least a twostep process, and there are many other factors involved. It involves the damage of the DNA either directly or indirectly by the agent. This damage is referred to as promutagenic lesions. In order to obtain an initiated cell, the damage must be fixed by replication.
The controversy over the for-mation of initiated cells is not in the formation of DNA damage but in this fixation step. How can the fixation occur? To bring this into focus with Ray Tennant's discussion (1) , when testing mutagenic chemicals with the in vitro test or the Ames test, you obviously do not take the fixation step into account, because the cells of the bacteria are dividing. So if DNA is damaged, mutations are more than likely to occur.
However, in the whole animal the fixation step itself could be the limiting step. Jim Swenberg was kind enough to lend me a few slides and I want to illustrate with formaldehyde that you must take this step into account (2) .
The tumor-response curve obtained with formaldehyde is very nonlinear. I will avoid using the word "threshold," but the slope here is probably approaching zero as the dose decreases. If you look at the promutagenic damage, i.e., the DNA adducts, the DNA adduct levels are fairly linear as you go to lower doses. Assume for purposes of argument that it is linear. Forget that it's formaldehyde. Thus, apparently, the formation of the promutagenic damage alone is not enough. But then, as Jim Swenberg and his co-workers have shown, the induction of cell turnover by formaldehyde is very dose dependent. In fact, the breaks in the tumor curve and in the curve showing the induction of cell turnover are similar. So at lower doses where you saw no tumor response, there was essentially no detectable induction of cell turnover.
Again, I should say Jim Swenberg has pioneered the approach to examine cell replication in chronic administration of chemicals with carcinogenic regimens. Obviously, from this set of data (and I think there are similar examples) you would conclude that promutagenic lesions exist, but tumors are not evident because the damage is not fixed.
This can even occur with one chemical in the same animal, for example, with the tobacco specific nitrosamine 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) (3) . There are three tumor induction sites with NNK in the Fischer rat, and they have very different dose responses. The induction of nasal cavity and liver tumors probably requires the induction of cell turnover by NNK, but apparently that is not the case in the lungs.
Suppose a compound that is mutagenic in the Ames tests and other short-term tests has a linear response as far as promutagenic lesions are concerned, yet the slope of the tumor-response curve is decreasing. This could be a result of the lack of induction of cell turnover at lower doses. The question is how to regulate the compound. Should you regulate it based on the tumor response or based on the promutagenic lesions?
Obviously, there are pros and cons to either strategy. Personally, I don't want to be walking around with promutagenic lesions. Several presentations during Mon There is another argument concerning the promutagenic lesions. An increasing amount of data shows that DNA damage could enter this process in several places. For example, the transformation of a benign tumor to a malignant tumor could result from a second-hit type phenomenon in the benign tumor. This is shown to be the case in the skin and liver systems, where second hit can increase the transformation from a benign tumor to a malignant tumor (6, 7) . Also, Julian Peto's data yesterday showed that older people exposed to radiation were more sensitive to tumor induction than younger people (unpublished observations). Thus, there is ample data to suggest that genotoxic lesions are also involved in the latter stages of malignancy.
The second issue I wanted to address about the multistep process concerns compounds that do not act by genotoxic mechanisms and are promoters but not cytotoxic promoters. I agree that if a compound induces tumors only by cytotoxicity at high doses, then the chemical is probably safe. The arguable point is how to pick out chemicals (e.g., 12-0-tetradecanoyl-phorbol-13-acetate (TPA); 2,3,7,8-tetra-chlorodibenzo-p-dioxin (TCDD); and hormonal promoters such as estrogen) whose mode of action is through specific receptors. How can we protect ourselves against compounds like TCDD? TCDD was completely negative in all genotoxic tests. I think at the doses administered in the bioassay studies, TCDD was not overly cytotoxic. So how can we identify this type of compound as having carcinogenic properties? One possible approach was outlined by Steve Reynolds in an earlier presentation at this conference (8) . Comparisons of activated oncogenes between spontaneously occurring tumors and chemically induced tumors have the potential to identify nongenotoxic, noncytotoxic chemicals. Steve outlined this approach for the B6C3F1 mouse liver model. However, the approach can obviously be utilized in other animal model systems.
The following is a brief description of this approach. Assume the incidence of mouse liver tumors increased from 30% in control to 70% in treated animals. Analysis showed that the pattern of activated oncogenes were the same in treated and controls. In addition, a careful analysis of cell turnover was done at the doses employed in the carcinogenesis study. If there was chemically induced cell turnover at the doses employed, one could argue that the chemical is just cytotoxically promoting these spontaneous lesions. But suppose there was no cytotoxicity, as with TCDD? In this case, the chemical may be doing something very specific, like acting through a receptor. We need to take advantage of some of these sensitive in vivo model systems to analyze individual steps in the carcinogenesis process. Discussion DR. RAYMOND TENNANT, NIEHS: In terms of the identification of tumor promoters, I think this is one excellent way, involving the mouse, at least. As a point of departure, I would really like to offer the possibility that the only thing that really separates a tumor promoter from a carcinogen is the dose rate at which it was applied. I just took a quick screen out of the NCI data base, the CCRIS. In there they list 94 substances classified as tumor promoters in any system, i.e., skin or any two-stage model system. Of those there have been 21 Kurt Randerath looked at the DNA adducts in the kidney after chronic exposure to these compounds and found that in both cases DNA adducts were detected by the postlabeling procedure. The interesting thing was that the adducts were the same in both cases, which means that they weren't arising from the estrogens. They were arising from estrogen-mediated influences on either dietary constituents or endogenous factors resulting in the formation of them. But, nevertheless, these might be promutagenic lesions. They might be involved in the carcinogenic process.
So in this case would you call those estrogens genotoxic or not genotoxic? To put it in your words, it doesn't make any difference to me whether I'm walking around with adducts that arose from a hormone or a dietary constituent than exposure to the chemical. So What you have in that slide was covalent bindings divided by exposure parts per million. So that it has a linear phase at the low end and a linear phase at the high end and a nonlinear portion in between there. And I think Marshall didn't get it quite right. Because the point was that it's linear at the high end. At 6 and at 15 ppm you have linear covalent binding, but you have a very nonlinear tumor response. And the only explanation that I can come up with is cell proliferation. I think it's a very reasonable one from a science standpoint. There's another point that needs to be made on your promutagenic adduct issue. We all must remember that all adducts are not created equal. They don't have equal potency, they don't have equal half-times, and they differ in different cell types and different tissues.
The examples range from 06-methylguanine, which ends up being persistent in brain at about 10% at the highest dose for 6 months. The cisplatin that you referred to. We have other adducts. We could take 06_ methylguanine in the liver, and it's virtually all repaired. It's first order, so there's always going to be a little something left over. We're not going to get rid of it all. And we have to bring in the efficiency for causing mispairing and the time that these adducts hang around in the tissues that they're causing the tumors in. It's a far more complex thing. And then you get into sitespecific mutagenesis. So as I said, we've got a tremendous way to go before we're ever there completely. DR. ALBERT: I think that the excitement about promoters in carcinogenesis from the risk assessment standpoint is that those agents that interact through cell receptor mechanisms give the promise of being able to define low-level dose response, which from a mechanistic standpoint in a way which contrast between a single molecule, single hit, process that we're essentially locked into.
The other comment I'd like to make is that although the interaction between adduct levels and cell proliferation makes a beautiful story, I think there ought to be some reservations about the extent to which it's applicable to different systems. We've just got some pilot data. Admittedly, it's pilot data. But the chronic application of benzo [a] 
